Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register

The National Registry of Patients with Inflammatory Bowel Disease (IBD) in the Russian Federation was established to study the epidemiological and clinical characteristics of patients and evaluate the actual clinical practice of medical and surgical treatment.

AIM: to analyze the data of patients with IBD in the Russian Federation including clinical and demographic characteristics, medical status of patients, the frequency of use of various classes of drugs and response to treatment, the survival rates of advanced therapy drugs and the reasons for their cancellation.

METHODS: from May 2017 to August 2021, depersonalized data of 3827 adult patients with IBD (ulcerative colitis (UC) – 2358 pts, Crohn's disease (CD) - 1469 pts) from 80 regions of the Russian Federation were included in the registry, both with previously and newly diagnosed UCor CD, who are in inpatient or outpatient care.

RESULTS: in our population, the ratio of UC: CD was 1.6:1. The distribution of patients by sex was the same. The average age of patients in the registry was 40.6±13.1 (13-83 years) for UC and 38.5±14.3 (15-75 years) for CD, the half of patients were in the age range of 21-40 years for both diseases. The average age of disease onset did not differ for UC and CD and was 35.3 year (12-75 years) and 31.2 year (14-72 years) respectively. The duration between the onset of symptoms and the establishment of a diagnosis was 13.2 months in UC, and statistically significantly longer in CD - 34.8 months (P<0.01). The proportion of smokers in CD patients was statistically significantly higher than in UC ones (14.6% versus 9.6%, respectively, P<0.001). The incidence of disability was also significantly higher in CD than in UC patients (41.7% vs. 29.8%, P<0.01). The diagnosis of mild UC was established in 36% of cases, moderate UC occurred in 48.9% of patients, severe UC in 14.2% of patients. For the first time, the frequency of acute severe UC (1%) was estimated. The majority of patients had total UC (56.8%), 33% had left-side colitis, and 9.4% had proctitis. CD was divided by localization into ileocolitis 55.9%, terminal ileitis 23.9%, colitis 20.2%, perianal lesions were noted in 32.5% of cases. The overall complication rate in CD was 46% (681 patients), of which the most common were strictures - 48% and fistulas- 25.1%.Frequencyof extra intestinal manifestations did not differ in UC and CD patients and was 20.1% (473 patients) and 24.5% (360 patients), respectively. Of these, musculoskeletal lesions were more common (41.6% in UC, 42% in CD), lesions of the skin, eyes, mucous membranes, liver, anemia were also noted. In the treatment of IBD, steroids were used most often (79.3% and 65% in UC and CD, respectively), followed by 5-ASA - 47% in UC, 32.4% in CD. Immunosuppressant’s in CD were prescribed significantly more often (28.4%) than in UC (11%) (p<0.05). Biologics were used in 20.6% of UC patients and in 30% of CD patients. The highest 2-year survival of advanced therapy was noted for ustekinumab in CD (96%), for tofacitinib in UC (89.3%), and for vedolizumab in both UC and CD (92.5% and 88.4% respectively). The survival rates of all TNF-α inhibitors were approximately the same and varied within 58.1-72.4% in UC and 60-70% in CD. The most common reasons for discontinuation of advanced treatment were lack of efficacy/loss of response in both UC and CD. The second common reason was achieving remission. Certolizumab pegol in CD was canceled for this reason most often- 22.7% of cases. A small number of patients discontinued treatment due to adverse events: for UC - 1 patient each on adalimumab, golimumab, and tofacitinib, and 7 patients on infliximab, for CD- 5 patients on infliximab and adalimumab (9.6% and 7.5%, respectively) and 2 patients (4.6%) on certolizumab. Unfortunately, the proportion of discontinuation for non-medical reasons was significant and varied from 7% to 50% for different drugs. In some patients, the reason for discontinuation of therapy remained unknown.

CONCLUSION: The difficulties of differential, often untimely diagnosis of CD and UC, the predominance of complicated and severe forms against the background of an increase in morbidity and prevalence, and at the same time the lack of adequate statistical accounting of CD and UC, make it necessary to create a unified clinical register of patients with IBD. The register of IBD patients will provide a holistic picture of the IBD situation in the country, including optimizing the use of budget funds for the treatment of patients with CD and UC, ensuring their rational planning.

1. New insights into inflammatory bowel disease. Ed by S.Huber. In Tech. 2016.

2. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33–47.

3. Molodecky NA, Soon IS, Rabi DM, Ghali WA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30.

4. De Groof EJ, Rossen NGM, Van Rhijn BD, et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a populationbased cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016;28:1065–72.

5. Qiu Y, Wen Ren W, Liu Y, et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. E Clinical Medicine. 2020;27. 100544 http://www.journals.elsevier.com/eclinicalmedicine

6. Burisch J, Jess T, Martinato M, Lakatos P. On behalf of ECCO — Epi Com. The burden of inflammatory bowel disease Europe. JCC. 2013;7:322–337

7. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769–78.

8. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28:1148–53.

9. Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: East meets West. Journal of Gastroenterology and Hepatology. 2020;35:380–389. doi: 10.1111/jgh.14872

10. Hammer T, William R. Inflammatory Bowel Disease. Epidemiology, Evaluation, Treatment, and Health Maintenance. N C Med J. 2016;77(3):198–201.

11. Hammer T, Nielsen KR, Munkholm P, et al. The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data. J Crohns Colitis. 2016;10(8):934–42.

12. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690–697.

13. Burisch J, Pedersen N, Čuković-Čavka S, et al. EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–97.

14. Knyazev O.V., Shkurko T.V., Fadeeva N.A., et al. Epidemiology of chronic inflammatory bowel diseases. Yesterday, today, tomorrow. Experimental and clinical gastroenterology. 2017;3:4–12. (in Russ.).

15. Plotnikova E.Yu., Chashkova E.Yu. Some aspects of the treatment of inflammatory bowel diseases. Lechaschii vrach. 2019;8:14–20. (in Russ.).

16. Belousova E.A., Khalif I.L., Abdulganieva D.I., et al. Sociodemographic characteristics, features of the course and treatment options for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(6). (in Russ.). doi: 10.18786/2072-0505-2018-46-6

17. Knyazev O.V., Belousova E.A., Abdulganieva D.I., et al. The real practice of drug therapy of moderate and severe forms of inflammatory bowel diseases in Russia, the Republic of Belarus and the Republic of Kazakhstan. Interim results of the INTENT study. Almanac of Clinical Medicine. 2021;49(7):443–454. (in Russ.). doi: 10.18786/2072-0505-2021-49-061

18. Betteridge JD, Armbruster SP, Maydonovitch C, et al. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 2013, 19(7):1421–7.

19. Lördal M, Cars T, Wettermark В. Gender Differences of IBD Care in the Healthcare Region of Stockholml. Am J Gasrtoenterol. 2014, Sa1118.

20. Khalif I.L., Shabina M.V., Golovenko A.O., et al. The course of chronic inflammatory bowel diseases and methods of their treatment used in the Russian Federation (Results of a multicenter population-based single-stage observational study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):54–62. (in Russ.). doi: 10.22416/1382-4376-2018-28-3-54-62

21. Abdulganieva D.I., Bakulev A.L., Belousova E.A., et al. Early administration of genetically engineered biological drugs in immune-inflammatory diseases: opportunities and prospects. The position of experts. Almanac of Clinical Medicine. 2020;48. (in Russ.). doi: 10.18786/2072-05-2020-48-050

22. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180

23. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1 — 106. doi: 10.1136/gutjnl-2019-318484

24. Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(4):635–42. doi: 10.1016/j.cgh.2014.03.037

25. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–61. doi: 10.1053/j.gastro.2020.01.006

26. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9(2):156–63. doi: 10.1093/ecco-jcc/jju016

27. Burisch J, Vegh Z, Pedersen N, et al. Health care and patients’ education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. JCC. 2014;8:811–818. doi: 10.1016/j.crohns.2013.12.023

28. Ye Y, Pang Z, Chen W, et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015;8(12):22529–22542.

29. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc, 2006;81:1462–1471. doi: 10.4065/81.11.1462

30. Biedermann L, Fournier N, Misselwitz B, et al. High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation — Data from the Swiss IBD cohort study. J Crohns Colitis. 2015;9:819–29. doi: 10.1093/ecco-jcc/jjv113

31. Higuchi LM, Khalili H, Chan AT, et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107:1399–1406. doi: 10.1038/ajg.2012.196

32. Ivashkin V.T., Shelygin Yu.A., Belousova E.A., et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4):7–36. doi: 10.33878/2073-7556-2019-18-4-7-36

33. Silverberg MS, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5–36.

34. Henriksen M, Jahnsen J, Lygren I, et al. IBSEN Study Group. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543–50. doi: 10.1097/01.MIB.0000225339.91484.fc

35. Safroneeva E, et al. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther. 2015;42:540–548.

36. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–9. doi: 10.1002/ibd.20036

37. Harbord M, Annese V, Vavricka SR, et al. and for the European Crohn’s and Colitis Organisation [ECCO]. The First European Evidencebased Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–254.

38. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011:60;1739–1753.

39. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflam Bowel Dis. 2015;21(8):1982–1992.

40. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liv Dis. 2008;40S:S253–59.

41. Levine J, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7:235–41.

42. Cohen R, Robinson DJ, Paramore C, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008;14 (738-43).

43. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016 Sep;175(3):487–92.

44. Magro F, Gionchetti P, Eliakim R, et al. for the European Crohn’s and Colitis Organization [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn’s and Colitis. 2017, V.11, Issue 6, pp. 649–670

45. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. https://gut.bmj.com/content/68/Suppl_3/s1 doi: 10.1136/gutjnl-2019-318484

46. Crohn’s disease. Clinical recommendations (Preliminary version). Koloproktologia. 2020;19(2):8–38. doi: 10.33878/2073-7556-2020-19-2-8-38

47. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113:481–517.

48. Gomollón F, Dignass A, Annese V, et al. on behalf of ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease. Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis. 2017;11, Issue 1:3–25.

49. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160:2496–2508.

50. Jung YS, Han M, Park S, et al. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Digestive Diseases and Sciences. 2020;65:1436–1444.

51. Ko Y, Paramsothy S, Yau Y, Leong RW. Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence AustralianNational IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021 Aug;54(3):292–301.

52. Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495–507.